Skip to main content
Top
Published in: BMC Health Services Research 1/2018

Open Access 01-12-2018 | Research article

Factors influencing the use of the “not for generic substitution” mention for prescriptions in primary care: a survey with general practitioners

Authors: Virgil Beauvais, Annabelle Marque, Guillaume Ferté, Jan Chrusciel, Julie Souille, Pierre Nazeyrollas, Stéphane Sanchez

Published in: BMC Health Services Research | Issue 1/2018

Login to get access

Abstract

Background

Generic drug substitution is a public health policy challenge with high economic potential. Generic drugs are generally cheaper than brand-name drugs. Drugs are a significant part of the total health expenditure, especially in ambulatory care. We conducted a cross-sectional study with general practitioners in the Champagne-Ardenne region to determine physician-related factors and beliefs causing doctors to use the Not for Generic Substitution (NGS) mention.

Methods

Questionnaires were sent to General Practitioners (GPs) practicing in Champagne-Ardenne via 3 shipments, from January 2015 to May 2015. Prescriber characteristics and beliefs influencing the use of the NGS mention were assessed for frequent (≥ 5%) and less frequent (< 5%) users of the NGS mention.

Results

Factors associated with above average NGS mention use in bivariate analysis included patient comorbidity, polypharmacy, a concern that generic and brand-name drugs are not bioequivalent and belief in higher efficacy of the brand name drug. The use of an e-prescribing system (EPS) and medical practice in rural areas appeared to be associated with lower use of NGS mention in bivariate analysis but not in multivariable analysis. In multivariable analysis, patient request was associated with a higher use of the NGS mention (NGS ≥ 5%, adjusted Odds Ratio (aOR) = 2.52; 95% CI = [1.46–4.35]; p = 0.001), which was also linked to patient age over 65 (NGS ≥ 5%, aOR = 2.33; 95% CI = [1.03–5.30]; p = 0.04). The NGS mention was often used for drugs where substitution is debated in the literature (thyroid hormones, antiepileptic drugs).

Conclusion

This work highlights the involvement of the doctor-patient pair for the use of the NGS mention. Patient request was the major reason for using the NGS mention, even though it was not always endorsed by prescribers. Further studies are needed to assess patient views on generic drugs and drug substitution, accounting for their health status and socio-economic condition, to help improve the relevance of the information available to them.
Appendix
Available only for authorised users
Literature
1.
go back to reference Le Garrec M-A, Bouvais M. Les comptes nationaux de la santé 2012. DREES; 2013. Le Garrec M-A, Bouvais M. Les comptes nationaux de la santé 2012. DREES; 2013.
2.
go back to reference Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. 2010. Committee for Medicinal Products for Human Use. Guideline on the investigation of bioequivalence. 2010.
3.
go back to reference Krauss GL, Caffo B, Chang Y-T, Hendrix CW, Chuang K. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol. 2011;70:221–8.CrossRef Krauss GL, Caffo B, Chang Y-T, Hendrix CW, Chuang K. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol. 2011;70:221–8.CrossRef
4.
go back to reference Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464–9.CrossRef Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464–9.CrossRef
5.
go back to reference Mutualité Française. Rapport 2012 sur les médicaments génériques. 2012. Mutualité Française. Rapport 2012 sur les médicaments génériques. 2012.
6.
go back to reference Cour des comptes. La diffusion des médicaments génériques : des résultats trop modestes, des coûts élevés. In: Rapport sur l’application des lois de financement de la sécurité sociale. La Documentation française; 2014. Cour des comptes. La diffusion des médicaments génériques : des résultats trop modestes, des coûts élevés. In: Rapport sur l’application des lois de financement de la sécurité sociale. La Documentation française; 2014.
7.
go back to reference Wouters OJ, Kanavos PG, McKEE M. Comparing generic drug Markets in Europe and the United States: prices, volumes, and spending. Milbank Q. 2017;95:554–601.CrossRef Wouters OJ, Kanavos PG, McKEE M. Comparing generic drug Markets in Europe and the United States: prices, volumes, and spending. Milbank Q. 2017;95:554–601.CrossRef
8.
go back to reference Shrank WH, Cadarette SM, Cox E, Fischer MA, Mehta J, Brookhart AM, et al. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med Care. 2009;47:319–25.CrossRef Shrank WH, Cadarette SM, Cox E, Fischer MA, Mehta J, Brookhart AM, et al. Is there a relationship between patient beliefs or communication about generic drugs and medication utilization? Med Care. 2009;47:319–25.CrossRef
9.
go back to reference Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003;25:2875–90.CrossRef Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003;25:2875–90.CrossRef
10.
go back to reference Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 2007;6:465–8.CrossRef Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol. 2007;6:465–8.CrossRef
11.
go back to reference Skaltsas LN, Vasileiou KZ. Patients’ perceptions of generic drugs in Greece. Health Policy Amst Neth. 2015;119:1406–14.CrossRef Skaltsas LN, Vasileiou KZ. Patients’ perceptions of generic drugs in Greece. Health Policy Amst Neth. 2015;119:1406–14.CrossRef
12.
go back to reference Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ perceptions of generic medications. Health Aff Proj Hope. 2009;28:546–56.CrossRef Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients’ perceptions of generic medications. Health Aff Proj Hope. 2009;28:546–56.CrossRef
13.
go back to reference Predictors of generic substitution. The role of psychological, sociodemographic, and contextual factors. Res Soc Adm Pharm. 2016;12:119–29.CrossRef Predictors of generic substitution. The role of psychological, sociodemographic, and contextual factors. Res Soc Adm Pharm. 2016;12:119–29.CrossRef
14.
go back to reference Chong CP, March G, Clark A, Gilbert A, Hassali MA, Bahari MB. A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance. Health Policy Amst Neth. 2011;99:139–48.CrossRef Chong CP, March G, Clark A, Gilbert A, Hassali MA, Bahari MB. A nationwide study on generic medicines substitution practices of Australian community pharmacists and patient acceptance. Health Policy Amst Neth. 2011;99:139–48.CrossRef
16.
go back to reference Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy Amst Neth. 2012;104:61–8.CrossRef Quintal C, Mendes P. Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy Amst Neth. 2012;104:61–8.CrossRef
17.
go back to reference Patients’ attitudes towards generic drug substitution in Japan. Health Policy. 2011;99:60–5.CrossRef Patients’ attitudes towards generic drug substitution in Japan. Health Policy. 2011;99:60–5.CrossRef
18.
go back to reference Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J. 2013;89:540–6.CrossRef Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J. 2013;89:540–6.CrossRef
19.
go back to reference Dunne SS, Shannon B, Cullen W, Dunne CP. Perceptions and attitudes of community pharmacists towards generic medicines. J Manag Care Spec Pharm. 2014;20:1138–46.PubMed Dunne SS, Shannon B, Cullen W, Dunne CP. Perceptions and attitudes of community pharmacists towards generic medicines. J Manag Care Spec Pharm. 2014;20:1138–46.PubMed
21.
go back to reference Sarradon-Eck A, Blanc M-A, Faure M. Users sceptical about generic drugs: an anthropological approach. Rev Epidemiol Sante Publique. 2007;55:179–85.CrossRef Sarradon-Eck A, Blanc M-A, Faure M. Users sceptical about generic drugs: an anthropological approach. Rev Epidemiol Sante Publique. 2007;55:179–85.CrossRef
23.
go back to reference Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ. 2018;360:k714.CrossRef Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ. 2018;360:k714.CrossRef
24.
go back to reference Rathe J, Larsen P, Andersen M, Paulsen M, Jarbøl D, Thomsen J, et al. Associations between generic substitution and patients’ attitudes, beliefs and experiences. Eur J Clin Pharmacol. 2013;69:1827–36.CrossRef Rathe J, Larsen P, Andersen M, Paulsen M, Jarbøl D, Thomsen J, et al. Associations between generic substitution and patients’ attitudes, beliefs and experiences. Eur J Clin Pharmacol. 2013;69:1827–36.CrossRef
25.
go back to reference Malhotra S, Cheriff AD, Gossey JT, Cole CL, Kaushal R, Ancker JS. Effects of an e-prescribing interface redesign on rates of generic drug prescribing: exploiting default options. J Am Med Inform Assoc JAMIA. 2016;23:891–8.CrossRef Malhotra S, Cheriff AD, Gossey JT, Cole CL, Kaushal R, Ancker JS. Effects of an e-prescribing interface redesign on rates of generic drug prescribing: exploiting default options. J Am Med Inform Assoc JAMIA. 2016;23:891–8.CrossRef
26.
go back to reference Boissel A, Fagnoni P, Guignard M-H, Lazzarotti A, De Messières S, Sgro C. Évaluation des bonnes pratiques de prescription de sortie en CHU : quels enjeux pour les traitements chroniques non substituables ? Pharm Hosp Clin. 2014;49:95–101. Boissel A, Fagnoni P, Guignard M-H, Lazzarotti A, De Messières S, Sgro C. Évaluation des bonnes pratiques de prescription de sortie en CHU : quels enjeux pour les traitements chroniques non substituables ? Pharm Hosp Clin. 2014;49:95–101.
27.
go back to reference Michelon H, Marcel J, Coudert M, Juillard K, Pochat L, Fernandez C, et al. Generic drugs at hospital discharge: assessment in geriatrics. Geriatr Psychol Neuropsychiatr Vieil. 2014;12:13–9.PubMed Michelon H, Marcel J, Coudert M, Juillard K, Pochat L, Fernandez C, et al. Generic drugs at hospital discharge: assessment in geriatrics. Geriatr Psychol Neuropsychiatr Vieil. 2014;12:13–9.PubMed
28.
go back to reference Spiegel W, Mlczoch-Czerny M-T, Jens R, Dowrick C. Quality circles for pharmacotherapy to modify general practitioners’ prescribing behaviour for generic drugs. J Eval Clin Pract. 2012;18:828–34.CrossRef Spiegel W, Mlczoch-Czerny M-T, Jens R, Dowrick C. Quality circles for pharmacotherapy to modify general practitioners’ prescribing behaviour for generic drugs. J Eval Clin Pract. 2012;18:828–34.CrossRef
29.
go back to reference Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol. 2016;15:365–72.CrossRef Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol. 2016;15:365–72.CrossRef
Metadata
Title
Factors influencing the use of the “not for generic substitution” mention for prescriptions in primary care: a survey with general practitioners
Authors
Virgil Beauvais
Annabelle Marque
Guillaume Ferté
Jan Chrusciel
Julie Souille
Pierre Nazeyrollas
Stéphane Sanchez
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2018
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-018-3652-2

Other articles of this Issue 1/2018

BMC Health Services Research 1/2018 Go to the issue